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INTRODUCTION 
 
` 
INTRODUCTION 
Cardiovascular disease accounts for approximately 12 million deaths 
annually & is the commonest cause of death globally. Previously considered 
a disease of the affluent, the past three decades have seen considerable 
decline in the incidence and prevalence of atherosclerotic coronary disease 
in the industrialized western world; whereas at the same time this problem is 
assuming epidemic proportions in the developing world.  
     
Asian Indians, whether living in their own country or elsewhere, have 
higher rate of coronary artery disease than any other ethnic groups studied 
(1-3). Not only CAD is more prevalent, it is more severe and occurs at a 
younger age in Asian Indians. (3) Even within India, the prevalence of CAD 
is not homogeneous and is two fold higher in southern parts. The higher 
prevalence of CAD in Asian Indians is accompanied by paradoxically, a 
lower prevalence of conventional risk factors such as hypertension, diabetes 
mellitus, hyperlipidemia and cigarette smoking (4,5). This suggests the 
prevalence of other risk factors. 
 
 Hyperinsulinemia and Insulin resistance have been associated with 
obesity, Type 2 diabetes mellitus, hypertension, hyperlipidemia and CAD, 
however the link between endogenous hyperinsulinemia and CAD in non-
diabetic adults is at best weak with conflicting results, perhaps suggesting 
ethnic differences.  
` 
Recent physiological studies have shown that many characteristics of 
insulin resistance syndrome are more prevalent in Asian Indians compared 
to Caucasians (13,14,15). Impaired glucose tolerance, elevated fasting 
plasma glucose and insulin clamp and other techniques, have all been 
observed in Asian Indian populations (16,17,18,19). In addition to decreased 
insulin sensitivity, Asian Indians have lipid abnormalities, including 
increased triglycerides, low HDL and increased LDL, all may contribute to 
CAD. The present study was designed to examine the relationship between 
Insulin sensitivity and coronary artery disease in non diabetic patients.   
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AIM OF THE 
STUDY 
 
 
` 
AIM OF STUDY 
 
To evaluate the association of plasma insulin and insulin resistance 
(IR) measured by Homeostasis Model Assessment (HOMA-IR) with 
coronary artery disease (CAD) in non diabetic subjects.  
 
To estimate whether insulin resistance alone without diabetes is an 
independent risk factor for Coronary artery disease. 
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REVIEW OF 
LITERATURE 
 
` 
REVIEW OF LITERATURE 
INSULIN ACTIONS: 
 Insulin has unique properties as a hormone when compared to other 
hormones. Insulin is an anabolic hormone, apart from glucose homeostasis, 
induces protein synthesis, lipogenesis and regulation of various genes.  
Insulin also has anti inflammatory and anti apoptotic actions & protects 
endothelial functions  
 
 Insulin regulates diverse physiological processes in mammals, 
including membrane transport, intermediary metabolism and cell growth and 
differentiation. The most conspicuous metabolic effects of insulin are 
associated with skeletal muscle, cardiac muscle, adipose tissue and liver 
either having stimulatory or inhibitory effect.  A surprising feature is that to 
date the only signalling component  known to be unique to insulin action is 
the insulin Receptor (IR) itself, which is widely expressed in mammalian 
cells, although levels vary greatly between cell types. Thus normal insulin 
action influences wide range of tissues and insulin resistance can adversely 
affect diverse tissue functions, though not all to same extent. 
 
THE INSULIN RECEPTOR FAMILY 
 The insulin receptor is a large, hetero tetrameric, transmembrane 
glycoprotein containing two types of subunits designated alpha 
` 
(Mr.140.kDa) and beta (95 k Da), linked by disulphide bonds in a beta - 
alpha - alpha- beta configuration (7). The IR binds insulin with high affinity 
and specificity and transmits a signal to the cytosol via its intrinsic tyrosine 
– specific protein kinase activity (8) This phosphorylates a number of 
intracellular substrates, most especiall                     
y the so-called insulin receptor substrates (IRS), which recruit and activate 
an array of signalling proteins containing Src homology – 2 (SH2) domains. 
(9).  Two signals have been shown to play major role in insulin action, 
namely those transmitted by enzyme phospho-inositide 3 kinase (PI 3-
kinase), which generates ptd  Ins (3,4,5) tris-phosphate at the cytosolic face 
of membrane and the guanine nucleotide exchange factor Grb2/sos which 
activates the small G-protein Ras.  These act as switch mechanism to change 
the “currency” of signalling from tyrosine phosphorylation to serine / 
threonine  phosphorylation of target proteins.  However these signals and the 
downstream signalling cascade involving protein kinase B and mitogen – 
activated protein kinases (MAPKs) have been implicated in the specific 
actions of Insulin.  
 
Metabolic and antiapoptotic effects of insulin are mediated by 
signalling pathway involving IRS proteins, (PI-3k), protein kinase B and 
mToR (Mamalian target of Rapamycin). In contrast, non metabolic,  
` 
` 
proliferative and mitogenic effects are mediated largely via  activation of 
Ras, Raf and mitogen activated protein kinase Erk -1, Erk-2.   
There is accumulating evidence that obesity associated insulin 
resistance reflects inhibitory influences on this pathway at the level of 
insulin receptor substrates (IRS). Insulin resistance syndromes described in 
adults are either type A IR due to defect in insulin signalling pathways or 
type  B  IR due to auto antibodies directed at insulin receptors.  
 
INSULIN RESISTANCE: 
 
 Insulin Resistance is defined as an inability of a known quantity of 
exogenous or endogenous insulin to increase glucose uptake & utilization in 
an individual as such as it does in a normal person. Both insulin resistance 
and decreased insulin secretion are genetically programmed. This program is 
modified by a variety of environmental factors especially diet and activity 
(11). 
 It was in 1988, at the Banting lecture of the American Diabetes 
Association Annual meeting, that “Dr Gerald Reaven” first proposed the 
concept that insulin resistance and compensatory hyperinsulinemia were the 
cornerstones of a plurimetabolic syndrome that included hyper 
triglyceridemia, reduced plasma HDL cholesterol levels, essential 
hypertension and some degree of glucose intolerance (12).  
` 
 
 The concept was first referred to as “syndrome X”, implied that the 
Insulin Resistance syndrome might be associated with significant elevation 
in the risk of cardiovascular disease. It was also suggested that a significant 
proportion of non-diabetic individuals in the general population perhaps as 
many as 2.5 percent, might display  some features of the syndrome. Both IR 
and decreased insulin secretion are genetically programmed which is 
modified by a number of environmental factors especially diet & 
activity(16). 
 
INSULIN RESISTANCE AND HYPERTENSION   
   
 The direct association between hyperinsulinemia, insulin resistance 
and essential hypertension that could not be attributed to confounding 
obesity was most convincingly demonstrated by Ferrannini and colleagues 
in 1987 (20). A number of epidemiological studies have also been 
demonstrated on the association between insulin levels and blood pressure 
(21).  
 It is unlikely that hyperinsulinemia directly causes hypertension and 
the relationship between insulin resistance and vascular dysfunction is not 
direct and simple. Patients with insulinoma do not tend to have hypertension 
(22). Nevertheless prospective studies have shown that individuals with 
` 
hyperinsulinemia have a risk of developing both hypertension and coronary 
events (23).    
Insulin Resistance is absent in secondary hypertension patients, but 
present in normotensive offsprings of essential hypertensive patients(24) 
suggesting that it may precede the development of high blood pressure.  
 
 
 
 
 
 
 
 
 
 
 
  
The relation between IR and hypertension relates to several different 
mechanisms. First it is important to note that insulin is a vasodilator, that is 
mediated by nitric oxide release from endothelial cells, when given  
intravenously to people of normal weight (25) with secondary effects on 
sodium absorption in the kidney (26). Evidence indicate that sodium 
` 
reabsorption is increased in white people but not in Africans or Asians. (27). 
In the setting of  Insulin  Resistance, the vasodilator effect of insulin can be 
lost (28), but renal effect is preserved (29). Because nitric oxide accounts for 
all of insulin induced vasodilation, it is likely that hypertension is result of 
partial nitric oxide deficiency or resistance (30).   
 
 Insulin also increases the activity of sympathetic nervous system (31) 
an effect that might also be preserved in the setting of  insulin resistance 
(32) due to hyperinsulinemia. In pathophysiological states such as obesity, 
the balance may be disrupted by enhanced sympathetic activation in 
response to hyperinsulinemia together with “blunting” of insulin mediated 
vasodilatation (Vascular insulin resistance).  
 
Insulin Resistance and Dyslipidemia 
 
 Insulin Resistance is associated with many lipid abnormalities, 
including increased triglycerides, low high density lipoprotein (HDL) 
cholesterol and increased lipoprotein (a), all of which may contribute to 
excess coronary artery disease (33,34).  
 
 In general, with increases in free fatty acid flux to the liver, increased 
production of apo B containing triglyceride rich VLDL occurs (35). The 
effect of insulin on this process is complex. In the setting of insulin 
` 
resistance, increased flux of free fatty acid to the liver increases hepatic 
triglyceride synthesis but under physiological conditions, insulin inhibits 
VLDL secretion in systemic circulation (36). This response in part is an 
effect of insulin on the degradation of apo B. Yet insulin is also lipogenic, 
increasing transcription of many genes related to triglyceride biosynthesis. 
  
 Additionally, Insulin Resistance could also reduce the concentration 
of lipoprotein lipase in peripheral tissues (ie in adipose tissue more than 
muscle). This alteration in lipoprotein lipase, however contributes less to 
hypertriglyceridemia than does overproduction of VLDL. Nevertheless 
hypertriglyceridemia is an excellent reflection of insulin resistance 
condition.  
 
 In the presence of hypertriglyceridemia, a decrease in the cholesterol 
content of HDL results from decreases in cholesteryl ester content of the 
lipoprotein core, with variable increase in triglyceride, making the particle 
small and dense, a function in part of cholesteryl ester transfer protein (38). 
This change in lipoprotein composition also results in an increased clearance 
of HDL from circulation (39). The relation of these changes in HDL to 
insulin resistance is probably indirect, arising in concert with changes in 
triglyceride rich lipoprotein metabolism.  
 
` 
 In addition to HDL, the composition of LDL is also modified in 
similar way. In fact, with fasting serum triglycerides >2mmol/L, almost all 
patients have a predominance of small dense LDL (40). This change in LDL 
composition is attributable to relative depletion of unesterified  and 
esterified  cholesterol and phospholipids, with either no change or an 
increase in LDL Triglyceride (41).  
 
 Small dense LDL is more atherogenic than buoyant LDL because 
(i) it is more toxic  to the endothelium, 
(ii) it is more able to transit through the endothelial basement membrane, 
(iii) it adheres well to glycosaminoglycans, 
(iv) it has increased susceptibility to oxidation,  
(v) it is more selectively bound to scavenger receptors in macrophages 
(42).  
 
 Hypertriglyceridemia is a major determinant of the distribution of 
LDL particles. The higher the fasting triglyceride level, the greater the 
preponderance of small dense LDL in total LDL concentration (43).  
 
Insulin Resistance and Obesity  
 
 Recent studies of body fat distribution have shown that insulin 
resistance is associated with central obesity and visceral fat (13,14) 
` 
importantly. The increase in central obesity often is not apparent from 
measurement of body mass index (BMI), which may be in the normal range  
as defined by standard weight tables and other readily available criteria 
(44,45). 
 
 International Association for the study of obesity and the international 
obesity task force defined central obesity as waist circumference > 8ocm for 
women and >90cm for men (46).  
 
 A distinction between a large waist due to increase in subcutaneous 
adipose tissue versus visceral fat is debated. This distinction can be made 
with computed tomography or MRI (47).  
 
 With increases in intra-abdominal or visceral adipose tissue, a higher 
rate of flux of adipose tissue derived free fatty acids to liver through 
splanchinc circulation would be expected, whereas increases in abdominal 
subcutaneous fat would release lipolysis products into the systemic 
circulation and avoid more direct effects on hepatic metabolism (ie glucose 
production, lipid synthesis, and secretion of prothrombotic proteins such as 
fibrinogen and plasminogen activator inhibitor - 1 (48)).  
 
 Despite these potential differences in mechanisms related to excessive 
abdominal adipose tissue distribution, the clinical diagnosis of metabolic 
` 
syndrome does not distinguish between increases in subcutaneous and 
visceral fat.  
 Yet perhaps by a mechanism related to free fatty acid flux and 
metabolism, the relative predominance of visceral rather than increase in 
adipose tissue with increasing waist circumference in Asians and Asian 
Indians (49) renders the relative prevalence of the syndrome higher than in 
African American men in whom subcutaneous fat predominate (50).  
 
 However, there is evidence that the elevated post prandial free fatty 
acid release in upper body obese women originates from the non-splanchnic 
upper body fat, and not from the visceral depot (51). These results suggest 
that visceral fat might be a marker for, but not the source of excess post 
prandial free fatty acid in obesity.  
 
The effect of insulin to reduce circulating Non Esterified fatty acid 
(NEFA) concentrations is an important part of coordination of metabolic 
processes that occurs after a meal.  At that time, glucose becomes the major 
oxidative fuel for skeletal muscle and it is appropriate that “substrate 
competition” from fatty acids is minimized. 
 
Also, plasma NEFAs are potent stimulus  for hepatic gluconeogenesis 
and glucose output and again this stimulus is not appropriate in  the 
` 
postprandial period when hepatic glucose output needs to be suppressed to 
maintain glucose homeostasis  
 
The plasma NEFA concentrations display a marked diurnal variation, 
the reverse of insulin concentration, with troughs after meals and peaks 
before the next meal. 
 
 
 
 
 
 
 
 
 
 
Randle’s hypothesis  
 
The glucose fatty acid hypothesis proposed by Randle et al in 1963 
attempted to delineate the relationship between increased non - esterified 
fatty Acids (NEFAs) and insulin resistance. Randle and co-workers 
conducted a series of invitro experiments in rat cardiac muscle that 
suggested substrate competition between NEFAs and glucose as an energy 
` 
source for muscle. These studies observed a relative increase in the rate of 
fat oxidation compared with carbohydrate metabolism in response to 
increase in NEFAs. In addition, studies revealed a reduction in insulin 
stimulated glucose uptake and utilization by the cardiac muscle.  
 
The mechanism by which NEFAs bring about insulin resistance may 
be explained by recent studies that reveal NEFAs, induce different isoforms 
of protein kinase C. These isoforms can interfere with the intracellular 
signalling pathway of insulin and ultimately block glucose transport activity.  
 
Insulin resistance and increased NEFA supply to liver are associated 
with increased prevalence of Non – alcoholic steatohepatitis (NASH), which 
contributes to liver fibrosis and cirrhosis in a proportion of patients.  
 
Insulin Resistance and Atherosclerosis  
 
 The risk of coronary artery disease is greatly increased in the type 2 
diabetes. In a study examining the seven year incidence of myocardial 
infarction, Haffner et al (54) reported that the 10 year risk of a non-diabetic 
subject without previous MI was 3.5 percent, if a subject had previously had 
an MI, the risk of a further event was 18.8 percent. In contrast in diabetic 
subjects without previous MI, the risk was comparable to that of a non 
diabetic post MI subject (20.2 percent), while the risk of second MI in a 
` 
diabetic subject was 45 percent. Thus, diabetes that is characterised by 
insulin resistance and hyperinsulinemia is associated with an accelerated risk 
of atherosclerosis.  
 
 
 
 
 
 
 
 
 
However, in patients without overt type 2 DM, the independent 
association between insulin resistance and atherosclerosis risk has been less 
easy to demonstrate. Nevertheless, there are now several good 
epidemiological studies that suggest that insulin resistance is an independent 
risk factor for cardiovascular disease. For example, surrogate measures of 
insulin resistance are associated with carotid artery intima-media thickness, 
a measure of atherosclerosis (55,56).  
 
 As yet there are no prospective data on the predictive role of insulin 
resistance on cardiovascular event rate, although the European group for the 
` 
study of insulin resistance (EGIR) is currently conducting a large 
multicenter study to address the issue.  
 
Adipokines and Insulin Resistance  
 
The adipose tissue is now regarded as a major endocrine organ and a 
variety of factors  released by adipose cells potentially mediate insulin 
resistance (57). Evidence suggest  that one or more of these adipokines 
could impair insulin signalling and cause insulin resistance early in pre 
diabetics. (58) These factors include tumour necrosis factor  TNF α, leptin, 
lnterleukin 6  (IL-6) and recently resistin  and adiponectin: HSL : hormone 
sensitive lipase, IL-6: interleukin - 6, LPL: lipoprotein lipase, NEFA non 
esterified fatly acids,  PAI-1, Plasminogen activator Inhibitor -1; SR: soluble 
receptor, TNF α tumour necrosis factor – alpha,   VLDL  -TG : very low 
density lipoprotein - triglyceride. However the precise role of these factors 
and the molecular mechanisms whereby they generate insulin resistance 
have remained elusive (59). Recently adiponectin has gained significance as 
a mediator of insulin sensitivity. Many studies reported lower levels of 
adiponectin in insulin resistant states and plasma adiponectin is inversely 
associated with overall and central fat distribution.  
 
` 
 
 
 
 
 
 
 
 
 
 
 
 
Dietary Factors in Insulin Resistance  
Obesity is strongly linked to impaired insulin sensitivity, but acute 
changes in total energy intake influence insulin independently of changes in 
body weight or fat mass. (59). 
 
A high intake of saturated fat reduces insulin sensitivity, but that of 
mono unsaturated and poly unsaturated fat are neutral or beneficial at least 
in the setting of moderate total fat intake  
 
The effect of carbohydrate are less clear. However, unrefined 
carbohydrate with a low glycemic index, whole grain and high fibre foods 
` 
appear to have beneficial effects on insulin sensitivity compared with more 
refined carbohydrates.  
 
There may also be an influence of specific micronutrients such as 
magnesium, chromium and vitamin E, however , the evidence is limited  
 
Exercise and Physical Activity 
 
Physical activity has a positive effect on risk factors and diseases, in 
obese population. Though the exact mechanism is not known, exercise has 
many benefits for health and CAD risk factors, and reduces cardiovascular 
morbidity and mortality.  
 
Exercise has a favorable action on modifying blood lipids, particularly 
HDL cholesterol in overweight individuals. Other studies have shown 
beneficial effect on blood pressure. Exercise has been shown to    increase 
insulin sensitivity, GLUT-4 concentration and glucose disposal (66). 
Regular physical exercise improves endothelial function, by increasing 
vasculature shear stress and by increased production of nitric oxide. (67).  
 
In overweight and insulin resistant subjects, exercise has been shown 
to reduce the  non traditional cardiovascular   risk factor homocysteine. It is 
known that regular exercise , even in overweight  individuals leads to an 
improvement in fibrinolytic system. (69).  
` 
However little is gained unless long term changes are established and 
this is known to be difficult to acheive in the majority of individuals. The 
compliance is generally poor. 
 
Measurement of Insulin Resistance 
 
 The concept of insulin resistance is relatively easy to understand, but 
determining precisely who is insulin resistant is more complicated (70).  
 
 A World Health Organization consensus group recently concluded 
that the insulin sensitivity index (SI) of the lowest 25 percent of a general 
population can be considered insulin resistant (71). The European group for 
the study of insulin resistance took a more restricted view, defining insulin 
resistance as the SI of the lowest 10 percent of a non-obese, non-diabetic, 
normotensive Caucasian population. Richard Legro and his associates also 
used the SI of the lowest 10 percent of an obese, non PCOS population to 
define insulin resistance (72).  
 
Hyperinsulinemic Euglycemic Clamp 
 
 The gold standard for evaluating insulin sensitivity, this clamp 
technique requires a steady intravenous infusion of insulin to be 
administered in one arm. The serum glucose level is “clamped” at a normal 
fasting concentration by administering a variable intravenous glucose 
` 
infusion ((73) in the other arm. Numerous blood samplings are taken to 
monitor serum glucose so that a steady “fasting” level can be maintained. (In 
theory the intravenous infusion should completely suppress hepatic glucose 
production and not interfere with the test’s ability to determine how 
sensitive target tissues are to the hormone).   
 
The degree of insulin resistance should be inversely proportional to 
the glucose uptake by target tissues during the procedure. In other words, the 
less glucose that is taken up by tissues during the procedure, the more 
insulin resistant the patient is. 
 
 The hyperinsulinemic - euglycemic clamp technique is most 
scientifically sound technique for measuring insulin sensitivity and it is 
against this standard that all other tests are usually compared Because this 
and similar “clamp” techniques are expensive, time consuming, and labour 
intensive, they are not very practical in an office setting. 
 
 To overcome these obstacles, alternative tests have been developed, 
including the frequently sampled intravenous glucose tolerance test 
(FSIVGTT), insulin tolerance test (ITT), insulin sensitivity test (IST), and 
continuous infusion of glucose with model assessment (CIGMA).  
Unfortunately all of these methods require intravenous access and multiple 
venipunctures, making them relatively impractical for office assessment.  
` 
The oral glucose tolerance test (OGTT) does not require intravenous access 
but does involve several venipunctures and 2 to 4 hours of patient and 
technician time.  Each of these tests have been shown to correlate reasonably 
well with dynamic clamp techniques. 
 
Non Dynamic Measurements of Insulin Sensitivity 
These tests, which include fasting insulin alone, are the HOMA test 
(homeostasis assessment model) (78 and 79) and the QUICKI (Quantitative 
Insulin Sensitivity Check Index). These tests are simple to perform, being 
based on fasting insulin and glucose measurements alone.  
 
 HOMA has been widely employed in clinical research to assess 
insulin sensitivity.  Rather than using fasting insulin or a G/I ratio, the 
product of the fasting values of glucose (GO) expressed as mg/dl and insulin 
(IO) expressed as mcU/ml is divided by a constant. 
 
IO x GO 
405 
 
 
 The constant 405 should be replaced by 22.5 if glucose is expressed in 
S.I. Units.  Unlike IO and the G/I ratio, the HOMA calculation compensates 
for fasting hyperglycemia.  The HOMA value correlates well with clamp 
techniques and has been frequently used to assess changes in insulin 
` 
sensitivity after treatment. HOMA has also been used to study insulin 
resistance among PCOS patients of differing ethnic origins. 
 Like HOMA, QUICKI can be applied to normoglycemic and 
hyperglycemic patients.  It is derived by calculating the inverse of the sum 
of logarithmically expressed values of fasting glucose and insulin: 
 
 
1 
{log (IO) + log (GO) } 
 
 Both HOMA and QUICKI values increase in the insulin – resistant 
patients. 
 
Ischemic Heart Disease 
 
Ischemic heart disease is defined as myocardial impairment due to 
imbalance between coronary blood flow and myocardial requirement. The 
commonest cause of IHD is atherosclerotic coronary artery disease  
 
Spectrum of myocardial ischemia.   
 
Traditionally, ischemic heart disease has been divided into  several 
seperate syndromes such as stable effort angina, unstable angina, non – Q 
wave MI and Q wave MI. The recent understanding  of the conversion of a 
stable atherosclerotic lesion to a plaque rupture with thrombosis has 
` 
provoked a unifying hypothesis for the aetiology of acute coronary 
syndrome.    
 
Nomenclature of myocardial ischemia 
 Old  Present  
Asymptomatic   Asymptomatic   
Stable effort angina  Stable effort angina  
Unstable angina  Acute coronary syndrome, unstable 
angina without  necrosis  
Non Q wave MI Non ST elevation MI (evidence of 
myocardial necrosis )   
Q wave MI  ST elevation MI  
Sudden death  Sudden death  
Silent ischemia  Ischemic cardiomyopathy  
 
 The concept of myocardial ischemia as a spectrum provides 
framework for understanding the pathogenesis, clinical features and 
outcome of patients  
 
Pathophysiology  
 
Atherosclerotic obstruction of the coronary arteries leads to a 
spectrum of clinical syndromes varying between effort or stable angina to 
acute coronary syndrome (ACS) where an atheromatous plaque becomes 
vulnerable to rupture and produces sudden, complete or partial occlusion of 
the coronary artery. A complete occlusion leads to ST elevation myocardial 
` 
infarction (STEMI) whereas partial occlusion leads to non – ST elevation 
myocardial infarction (NSTEMI)  
 
Site & size of MI 
Left anterior descending (LAD)  - Antroseptal MI 
Left circumflex artery    - Anterolateral MI 
Right coronary artery    - Inferoposterior wall MI 
        with or without RVMI     
` 
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AND METHODS  
 
 
 
` 
MATERIALS AND METHODS 
The study was conducted at the out patient department of cardiology 
at Government Royapettah Hospital.   
 
Selection of Cases  
 A total of fifty patients with coronary artery disease were chosen from 
the outpatient department of cardiology.   
 
Fifty healthy controls matched for age and glycemia were chosen 
from the master health check up at Government Royapettah hospital. 
  
Women chosen for the study were in the post menopausal age group 
or in follicular phase of their menstrual cycle to decrease the potential 
influence of gonadal steroids on insulin action.  
 
Inclusion criteria  
Coronary artery disease in the study was defined as: 
1) Documented myocardial infarction, substantiated by Q waves in 
electrocardiogram (ECG) and / or regional wall motion abnormality 
on echocardiogram,  
2) Angina supported by (i) ST depression or T wave inversion and/or  
(ii) coronary angiographic evidence of >70% stenosis of one or more 
vessels.  
` 
A control was defined as an induvidual without  a history of angina 
and with a normal ECG  
 
Exclusion criteria 
(i) Diabetes Mellitus, which was diagnosed according to American 
diabetes association (80) 
(ii) Patients with fasting plasma glucose over 110 mg/dl.  
(iii) Acute heart failure  
(iv) Hepatic dysfunction  
(v) Serum creatinine>1.4 mg/dl 
(vi) Patients receiving hormone replacement therapy  
(vii) Patients on antidiabetic agents or steroid therapy 
(viii) Patients who had an acute coronary event in the past 6 weeks.  
 
 A detailed history and physical examination was carried out in each 
patient including measurement of blood pressure, height  and weight. All the 
candidates were screened for blood chemistry abnormalities.   
 
Anthropometric measurements  
Height and weight were measured by standard procedures. Body mass 
index was calculated by using the formula  
Weight in kg BMI= (Height in m)2 
 
` 
The waist to hip circumference ratio (WHR) was measured using a 
flexible tape. The waist circumference  was measured in the horizontal plane 
above the iliac crest. The hip circumference was measured at the maximum 
circumference at the level of the femoral trochanters.  
 
Biochemical Analysis 
 
In our patients, samples were collected from venous  blood after 
overnight fasting and blood chemistry  was performed. Fasting blood sugar 
was measured by enzymatic oxidase  method. The concentrations of serum 
lipids including total cholesterol, triglyceride, HDL cholesterol &LDL - 
cholesterol were measured. LDL cholesterol was calculated using Fridewald 
formula. Insulin was estimated by ELISA assay. 
Insulin resistance was calculated by the homeostasis model 
assessment of insulin resistance (HOMA-IR), proposed by Mattews et al., 
whose formula was (78). 
Fasting glucose (mgldl) x fasting insulin (µU/ml) HOMA -IR = 405 
                  
 
Fasting insulin and HOMA –IR were used as surrogate markers of 
insulin resistance in our study. 
 
` 
 
 
 
 
 
 
 
 
STATISTICAL 
ANALYSIS 
 
` 
 
STATISTICAL ANALYSIS 
Data were expressed as mean ± SD or geometric mean (95% 
confidence interval). The case and control group were analyzed using 
unpaired t tests. The categorical variables were analyzed using x2 or Fisher 
exact test. The association between insulin resistance and all other 
parameters were first analyzed by univariate analysis. Multivariate analysis 
to evaluate associations of CAD was performed by using multivariate 
logistic regression tests. A p value <0.05 was considered statistically 
significant.  
` 
 
 
 
 
 
 
 
 
 
OBSERVATIONS
AND ANALYSIS  
 
` 
OBSERVATIONS AND ANALYSIS  
Clinical characteristics of the study subject and baseline laboratory 
results are given in Tables l and 2. 
Group = Control Group 
Table -1 
Descriptive statistics 
 N Mean Std. Deviation  
AGE  
BMI  
WHR  
SBP 
DBP 
HDL  
LDL  
TGL  
TC  
FBS 
SI 
HOMA-IR 
Valid N (listwsie) 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
51.1800
27.4908
.7390
125.1600
79.0000
41.6600
97.5200
143.9400
189.4800
91.7800
11.4140
2.6974
5.95798 
3.124834 
.08229 
15.05956 
6.46813 
3.05467 
12.09021 
23.70861 
30.79109 
8.62907 
2.49399 
.55524 
 
` 
Group = Case Group 
Table – 2 
DESCRIPTIVE STATISTICS  
 N Mean Std. Deviation  
AGE  
BMI  
WHR  
SBP 
DBP 
HDL  
LDL  
TGL  
TC  
FBS 
SI 
HOMA-IR 
Valid N(listwsie) 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
51.600
24.4288
.8452
126.0000
78.6000
32.2800
100.5600
174.8600
204.3400
100.5600
21.6040
5.3952
6.91641 
3.03031 
.09943 
13.09307 
5.34907 
3.72548 
20.26272 
27.86557 
41.26352 
6.07827 
6.23892 
1.75469 
 
` 
In the studied subjects age wise distribution of patients were as follows 
Table - 3 
Frequency table 
Age Cases Control 
40-50 24 21 
50-60 20 26 
>60 6 3 
 
 COMPARISON OF AGE: T TEST  
GROUP STATISTICS 
Group N  Mean  Std. Deviation Std. Error Mean 
AGE      Case Group  
              Control Group  
50 
50 
51.6000 
51.1800 
6.91641 
5.95798 
.97813 
.84259 
p value : 0.746  
 
p-Value of 0.746 indicates the difference in age across case and 
Control groups is not significant. In other words both Case and Control 
groups have subjects with similar age group.  
` 
` 
Comparison of BMI (T test) 
Table - 5 
Group Statistics  
Group N  Mean  Std. Deviation Std. Error Mean 
BMI      Case Group  
              Control Group  
50 
50 
24.4288 
27.4908 
3.03031 
3.124834 
.42855 
4.41918 
p. Value : 0.494  
 
p-Value of 0.494 indicates the difference in BMI across Case and 
Control groups is not significant (i.e.,) the BMI of subjects in Case and 
Control groups is the same.   
 
Comparison of WHR  (T test) 
Table 6 
Group Statistics  
Group  N Mean Std. Deviation Std.Error Mean 
WHR      Case Group 
               Control Group  
50 
50 
.8152 
.7390 
0.09943 
0.8229 
.01406 
.01164 
p-Value <0.01 
p- Value less than 0.01 indicates the difference in WHR across Case 
and Control groups is highly significant (Significant at 1%). The group 
statistics table shows Case group is associated with higher waist to hip ratio 
than  control group inspite of having normal BMI, indicating a tendency 
towards central obesity. 
` 
Comparison of SBP (T test) 
 
Table – 7 
GROUP STATISTICS  
Group N  Mean  Std. Deviation  Std. Error Mean  
SBP        Case Group  
               Control Group  
50 
50 
126.0000 
125.1600 
13.09307 
15.05956 
1.85164 
2.12974 
p-Value: 0.767 
p-Value of 0.767 indicates the difference in SBP across Case and 
Control group is not significant.  
 
Comparison of DBP (T test) 
 
Table – 8 
GROUP STATISTICS  
Group N  Mean  Std. Deviation  Std. Error Mean 
DBP       Case Group  
               Control Group  
50 
50 
78.600 
79.0000 
5.34904 
6.46813 
.75647 
.9473 
p - Value : 0.737 
 
p- Value of 0.737 indicates the difference in DBP across Case and 
Control groups is not significant.   
   
 
` 
Comparison of HDL (T test) 
Table – 9 
GROUP STATISTICS  
Group N  Mean  Std. Deviation Std. Error Mean  
HDL      Case Group  
              Control Group  
50 
50 
32.2800 
41.660 
3.72548 
3.05467 
.52686 
.43200 
p value : <0.01 
 
p-Value less than 0.01 indicates the difference in HDL across Case 
and Control groups is highly significant (Significant at 1%). The Group 
statistics table shows Case group is associated with lower HDL than control 
group.   
Comparison of LDL (T test) 
Table – 10 
GROUP STATISTICS  
Group N  Mean  Std. Deviation  Std. Error Mean  
LDL      Case Group  
              Control Group  
50 
50 
100.5600
97.5200 
20.26272 
12.09021 
2.86558 
1.70981 
 p - Value : 0.365 
p-Value of 0.365 indicates the difference in LDL across Case and 
Control groups is not significant.  
 
` 
Comparison of TGL (T test) 
Table -11 
Group  N  Mean  Std. Deviation  Std.Error Mean 
TGL      Case Group  
              Control Group  
50 
50 
174.8600 
143.9400 
27.86557 
23.70861 
3.94079 
3.35290 
p - Value  <0.01 
 
p-Value less than 0.01 indicates the difference in TGL across Case 
and Control groups is highly significant (Significant at 1%). The Group 
statistics table shows Case group is associated with higher TGL than control 
group.  
Comparison of  TC (T test) 
Table – 12 
GROUP STATISTICS  
Group  N  Mean  Std. Deviation  Std. Error Mean  
TC       Case Group  
            Control Group  
50 
50 
204.3400
189.4800
41.26352 
30.79109 
5.83554 
4.35452 
p -Value : 0.044  
 
p-Value less than 0.044 indicates the difference in TC across Case and 
Control groups is significant (Significant at 5%). The Group statistics table 
shows Case group is associated with higher TC than controls.  
` 
Comparison of FBS (T test) 
Table - 13 
Group  N  Mean  Std. Deviation  Std.Error Mean 
FBS      Case Group  
            Control Group  
50 
50 
100.5600
91.7800 
6.07827 
8.62907 
.85960 
1.22033 
P value <0.01 
P-Value less than 0.01 indicates the difference in FBS across Case 
and Control groups is highly significant (Significant at 1%); The Group 
statistics table shows Case group is associated with higher FBS than control 
group though it was lower than in diabetics.  
 
Comparison of SI (T test) 
    Table – 14 
GROUP STATISTICS 
Group  N  Mean  Std. Deviation  Std.Error Mean 
SI         Case Group  
             Control Group  
50 
50 
21.6040 
11.4140 
6.23892 
2.49399 
.88232 
.35270 
p -Value :<0.01 
 
p-Value less than 0.01 indicates the difference in SI across Case and 
Control groups is highly significant (Significant at 1%). The Group statistics 
table shows Case group is associated with higher SI than control group.  
` 
Comparison of  HOMA – IR (T test) 
Table - 15 
Group  N  Mean Std. Deviation Std.Error Mean 
HOMA-IR  Case Group  
                     Control Group 
50 
50
5.3952
2.6974
1.75469 
.55524 
.24815 
0.7852 
p value : <0.01 
 
p-Value less than 0.01 indicates the difference in HOMA-IR across 
Case and Control groups is highly significant (Significant at 1%). The 
Group statistics table shows Case group is associated with higher HOMA-IR 
than control group.  
 
 
 
 
 
 
 
 
 
 
 
` 
Categorical Variables Analysed By Chi Square Test 
Table - 16 
Group  
Control 
Group  
Case Group 
 
Total 
Gender 
 
Female Count 
            Expected count  
18
19.0
20 
19.0 
38
38.0
  Male Count   
         Expected count  
      
32
31.0
30 
31.0 
62
62.0
Total 
 
    Count  
    Expected Count   
 
50
50.0
50 
50.30 
100
100.0
 
 
Table - 17 
 Value dt Asymp. Sig (2 sided ) 
Exact sig 
(2sdides ) 
Extract sig 
(1sides) 
Pearson chi-square 
Continuity correction 
Likelihood Ratio 
Fihser’s exact test  
Linear- by – Linear 
association  
N of valid cases 
.170
.042
.170
.168
100
1
1
1
1
.680
.837
.680
.682
 
 
 
.837 .418
 
Based on Pearson Chi-Square test, p-Value of 0.680 indicates the 
difference in gender across case and control groups is statistically not 
Significant  
` 
` 
 
Table - 18 
Group  
Control 
Group 
Case 
Group 
Total 
FAM-HIST   Negative   Count  
                                     Expected Count 
38
33.0
28 
33.0 
66
66.0
                    Positive    Count                  
                                     Expected Count
12
17.0
22 
17.0 
34
34.0
 Total                           Count  
                                     Expected Count
50
50.0
50 
50.0 
100
100.0
 
 
Table - 19 
 Valu
e 
Dt. Asymp. Sig 
(2 sided ) 
Exact sig 
(2sdides ) 
Extract sig 
(1sides) 
Pearson chi-square 
Continuity correction 
Likelihood Ratio 
Fihser’s exact test  
Linear- by – Linear 
association 
N of valid cases 
4.456 
3.610
4.506
4.412
100
1
1
1
1
.035
.057
.034
 
.036
 
 
 
.057 .028
 
Based on Pearson Chi-Square test, p-Value of 0.035 indicates the 
difference in distribution of Family History across Case and control groups 
is statistically significant (at 5%), from the chart of distribution we can 
conclude that the case group has higher cases of positive family history than 
controls.     
` 
` 
 
 
 
Table - 20 
Group  
Control 
Group 
Case 
Group 
 
 
Total 
SMOKING   Negative   Count  
                                       Expected Count 
36
32.0
28 
32.0 
64
64.0
                     Positive     Count 
                                       Expected Count 
14
18.0
22 
18.0 
36
36.0
Total                              Count  
                                      Expected Count 
50
50.0
50 
50.30 
100
100.0
 
 
Table - 21 
 Value dt Asymp. Sig 
(2 sided ) 
Exact sig 
(2sdides ) 
Extract sig 
(1sides) 
Pearson chi-square 
Continuity Correction 
Likelihood Ratio  
Fisher’s Exact Test   
Linear- by – Linear 
association  
N of valid cases 
2.778 
23127
2.795 
 
2.750 
 
100 
1 
1 
1 
 
1 
.096 
.145 
.095 
 
.097 
 
 
 
.144 
 
 
 
.072 
 
Based on Pearson Chi-Square test, p-Value of 0.096 indicates the 
difference in smoking across case and control groups is statistically not 
significant.  
` 
` 
 
Table - 22 
Group  
Control 
Group 
Case 
Group 
 
Total 
ALCOHOL  Negative  Count  
                                      Expected Count
37
35.0
33 
35.0 
70
70.0
                    Positive    Count 
                                   Expected Count 
13
15.0
17 
15.0 
30
30.0
 Total                          Count  
                                   Expected Count 
50
50.0
50 
50.30 
100
100.0
 
Table - 21 
 Value dt Asymp. Sig (2 sided ) 
Exact sig 
(2sdides ) 
Extract sig 
(1sides) 
Pearson Chi-square 
Continuity Correction 
Likelihood Ratio 
Fisher’s exact test  
Linear- by - Linear 
association  
N of valid cases 
.762b 
.429 
.764 
 
.754 
 
100 
1 
1 
1 
 
1 
.383 
.513 
.382 
 
.385 
 
 
 
.513 
 
 
 
.257 
 
Based on Pearson Chi – Square test, p- Value of 0.383 indicates 
alcohol consumption do not differ across case and control group. 
` 
` 
Multivariate Analysis – Multiple Linear Regression  
A multiple linear regression analysis was performed to study the 
association between coronary artery disease case group and HOMA-IR by 
controlling for all other factors.  
 
Table - 24 
COEFFICIENTS 
Unstandardized 
Coefficients 
Standardized 
coefficients   
Model 
B Std. Error Beta 
 
 
t 
 
 
Sig. 
1 constant) 
AGE 
GENDER  
FAM-HIST  
SMOKING  
ALCOHOL 
BMI 
WHR  
SBP 
HDL 
LDL 
TGL 
TC 
FBS 
GROUP  
-7.941
.032
-.246
-.073
.122
.004
.002
3.077
.005
-.058
.021
.006
-.005
.074
1.092
1.984
.018
.258
.235
.257
262.
.005
1.398
.008
.034
.010
.008
.005
.016
.465
.111
-.064
-.018
.031
.001
.025
0.162
0.37
-.180
.188
.088
-.107
.340
.293
-4.003 
1.795 
-.954 
-.309 
.473 
.015 
406 
2.201 
609 
-1.695 
2.128 
.670 
-1.070 
4.511 
2.348 
.000
.076
.343
.758
.637
.988
.686
.030
.544
.094
.036
.504
.287
.000
.021
a. Dependent Variable: HOMA -IR  
` 
Variable named as “Group” is the indicator for coronary artery 
disease. Coding of Group is given by Group = 1 for case Group and          
Group = 0 for control group.  
 
 Based on the multivariate controlled study, after controlling for all 
other factors the difference in HOMA-IR between the case and control 
group is significant.  Based on the p-value of 0.021 for Group variable and a 
positive regression coefficients of 1.092 suggests that we can conclude at 
5% level of significance that the Coronary artery disease (case group) is 
associated with higher HOMA-IR and the case group has on an average 
1.092 units of HOMA-IR higher than the control group. 
` 
 
 
 
 
 
 
  
 
 
DISCUSSION 
 
 
` 
DISCUSSION 
 Insulin resistance plays an important role in promoting CAD and the 
degree of insulin resistance correlates with the severity of CAD. (81). 
Insulin resistance has been considered to promote atherosclerosis by directly 
affecting blood vessels.  The relationship between insulin resistance and 
atherosclerosis has been studied from various aspects.  Hyperinsulinemia is 
an only indirect indicator of insulin sensitivity.  Several large scale studies 
have revealed that hyperinsulinemia is closely associated with the mortality 
due to cardiovascular disease (82). 
 
 To date, however, few large scale studies have been conducted to 
examine the relationship between insulin resistance and coronary heart 
disease.  Recently, IRAS (Insulin Resistance Atherosclerosis study) group 
has conducted large-scale epidemiological studies, and has reported that 
insulin resistance rather than insulin concentration is an independent 
powerful risk factor for coronary heart disease.(83).  
 
 There are different theories as to how insulin resistance affects 
coronary artery disease (84). Insulin resistance is related to the vasomotor 
dysfunction of the endothelial cells that line the coronary artery (85). It is 
well known that endothelial function is impaired in patients with coronary 
artery disease. In our study, we evaluated the effect of impaired glucose 
` 
metabolism and insulin resistance that may play some role in the 
pathophysiology of CAD. We found increased fasting insulin levels in 
patients with CAD. Increased insulin resistance may play at least some role 
in patients with CAD.  
 
 Recent evidences indicate that insulin resistance is linked to 
untraditional CAD risk factors and possibly pro-atherosclerotic 
inflammatory state. Study conducted by Prof. Sidhartha Das and colleagues 
in angiographically established patients with CAD revealed the prevalence 
of IR in 40% and hyperinsulinemia in 50% of subjects having 
angiographically proven IHD who were normoglycemic.   
 
 
Risk factors for CAD in Angiographically proved cases with IHD  
Obesity (WHR)     100%   
BMI      40%    
HTN       60%   
TC > 200     20%   
LDL > 100      70% 
TGL > 150      40% 
HDL < 40     60% 
Smoking      20% 
Insulin resistance (HOMA IR >2.5)  40% 
` 
Mircoalbuminuria     20% 
Hyper insulinemia  (>9 µu/ml)  50% 
 
In another study, Yazici et al (86) investigated the relationship 
between the degree of slow coronary flow (SCF) and serum insulin, glucose 
and lipid levels. As a result, they found no correlations between corrected 
TIMI frame count and serum insulin, glucose and lipid levels. However they 
measured only basal serum insulin, not insulin resistance, without 
homeostatic models. On the other hand, evaluating insulin resistance by 
homeostatic modelling is more reliable than the standard method because 
both fasting glucose and insulin levels are integrated (87). 
  
 According to Take zako et al; the profile of insulin resistance based 
on HOMA – IR model was correlated with severity of coronary 
atherosclerosis based on Gensini’s score (88).  
 
 Other studies have reported that the incidence of major adverse 
cardiac events  (MACE) following  Percutaneous  Coronary  Intervention 
was higher in non –diabetic patients with high concentration of HbA1C than 
those with low concentration of HbA1C although these studies did not 
evaluate using insulin resistance (89).   Here, the concentration of HbA1C 
was lower in non-diabetic patients than in diabetic patients although it was 
high.  
` 
Some studies have reported that hyperinsulinemia and insulin 
resistance measured by HOMA are closely associated with restenosis 
following stenting in non diabetic patients (90, 91). A study from Finland   
found a significantly increased risk of ischemic loop to loop pdf disease in 
individuals who had hyperinsulinemia.  
 
The Rancho-Bernardo study found no association between insulin 
levels and cardiovascular disease in women and an inverse association  
between post challenge insulin levels and cardiovascular disease in men 
(higher insulin levels were protective). Likewise, no association was found 
in the 3 studies that presented data on men and women combined; the study 
from Finland, the study of  Pima Indians, and the Sand  Luis valley study. It 
is possible that some of these differences   reflect ethnic or geographic 
variation between the studies.  
 
Another preliminary study from North India by Rajiv Mahajan & 
colleagues showed no significant association between fasting insulin and 
CAD. Similarly there was no significant relationship between HOMA – IR 
and CAD. However in this study, in addition to excluding diabetes, they 
excluded hypertension and obesity (BMI>25), as both are also 
independently associated with hyperinsulinemia. They did not find a 
significant association between hyperinsulinema and CAD. 
` 
 
 
 
 
 
 
 
 
  
 
SUMMARY 
 
` 
SUMMARY 
 
 Age and sex distribution between the two groups (cases and controls) 
were similar. 
 
 There was a significant difference in the distribution of family history 
across cases and control group suggesting a higher prevalence of family 
history of coronary artery disease in cases. 
 
 There was no difference in the prevalence of smoking between the 
cases and controls group. 
 
 Although there was no difference in body mass index (BMI) between 
the two groups, waist to hip circumference ratio was higher in case group 
than in control group suggesting higher prevalence of central obesity in 
cases with coronary artery disease. 
 
 Case group had on an average high total cholesterol and triglyceride 
and lower HDL cholesterol which was  statistically significant than control 
groups.  Though LDL was higher in cases it was not statistically significant. 
 
 Fasting Blood sugar was significantly higher in cases than in controls 
although it was lower than in patients with diabetes. 
 
 Fasting insulin and Insulin Resistance (HOMA –IR) were 
significantly higher in cases than in controls. 
` 
 Although family history, HDL, TGL, TC, FBS attained significance 
in univariate  analysis, only WHR, LDL cholesterol and fasting blood sugar 
were significantly correlated with insulin resistance in multivariate analysis. 
` 
 
 
 
 
 
 
 
 
 
 
 CONCLUSION 
 
 
` 
CONCLUSION 
 
Thus fasting insulin levels and insulin resistance measured by 
homeostatic model assessment (HOMA-IR) are higher in patients with 
coronary  artery disease compared to controls.   
 
The mechanism by which insulin resistance provokes cardiovascular 
disease is mainly associated with the development of metabolic syndrome. 
 
Insulin resistance is significantly associated with cardiovascular 
disease   risk, even in the absence of diabetes, probably insulin resistance 
alone without diabetes can be considered as a coronary heart disease – risk 
equivalent in future.   
 
Our study proves that non-diabetic patients with insulin resistance 
exhibit high concentration of serum triglyceride and low concentration of 
HDL cholesterol. The present study has shown that the value of HOMA- IR 
was correlated with levels of triglyceride and inversely correlated with that 
of HDL cholesterol 
` 
 
 
 
 
 
 
 
 
 LIMITATIONS 
OF THE STUDY 
 
` 
LIMITATIONS OF THE STUDY 
 
The limitation of the present study is that it examined only a small 
number of patients. To date only few studies have been conducted to 
examine whether insulin resistance is correlated with coronary artery 
disease. Thus it can be taken as a preliminary study for further large scale 
studies.    
 
The present study failed to testify the reproducibility since it did not 
measure the value of HOMA –IR in a repetitive manner. The concentration 
of serum glucose and insulin can be altered at each different measuring   
time, although the present study measured them only once. However 
HOMA-IR index is well reflected in euglycemic hyperinsulinemic clamp 
test, a standard test and the clinical usefulness has been well established.  
 
 
 
 
 
  
` 
 
 
 
 
 
 
 
 
BIBLIOGRAPHY 
 
` 
BIBLIOGRAPHY 
1. Enas EA, Yusuf S, Mehta JL. Prevalence of coronary artery disease in 
Asian Indians Am. J.Cardiol 1992; 70: 945-949. 
2. Jha P, Enas E, Yusuf S.Coronary artery disease in Asian Indians: 
Prevalence and Risk factors. Am Pac. Isl J Health 1993;1:163-175. 
3. Enas EA, Mehta J. Malignant Coronary artery disease in young Asian 
Indians thoughts on pathogenesis, risk factors of coronary artery 
disease Am.J.Cardiol 1994;4:174-178. 
4. Mc Keigue PM 1996 Metabolic consequences of obesity and body fat 
pattern: lessons from migrants studies, Ciba Found symp 201:54-64; 
discussion 64-67, 188-193. 
5. MC keigu PM, Shah B,Marmot MG 1991 Relation of central obesity 
and insulin resistance with high diabetes prevalence and 
cardiovascular risk in south Asians. Lancet 337:382-386. 
6. Nakae J, Kido Y and Accili D (2001) Distinct and overlapping 
functions of Insulin and IGF –I receptors Endocrine Rev 22, 818-835 
7. White , M.F. (2002) IRS proteins and the common path to diabetes 
Am J physiol Endocrinol metab 283, E413-422. 
8. Van obberghen E Baron V Delahyes L Emanceelli B, Filippa, N 
Giorgetti- Peraldi S., Lebrun I., Mothe-Satney I., Peraldi P Rocchi 
` 
S,Saioka- Verhelle D., Tartare- Deckert S-and Guidicett.J J.(2001)  
Surfing the insulin  signaling web. Eur J clin Invest 31, 966-977. 
9. Siddle K., Urso. B., Niesler A., Cope, D.L., Molina. L., Suriyana, 
K.H. and Soos., M.A., (2001) Specificity in Ligand binding and 
intracellular signalling insulin and insulin like  growth factor 
receptors. Biochem sec Trans 29, 513-525. 
10. Saltiel  A.R and kahn C.R (2001) insulin signaling and the regulation 
of glucose and lipid metabolism Nature 414,799-806. 
11. Reaven G.M (1988). Role of insulin resistance in human disease. 
Diabetes 37, 1495-1507. 
12. Kahn CR insulin action, diabetogens , and the cause of type 2 diabetes 
Diabetes 1994;43:1066-1084. 
13. Banerji MA., Faridi N, Atlun R, Chaiken RL, Lebovitz H.E 1999. 
Body composition,  Visceral fat, Leptin and insulin resistance in 
Asian Indians men J.Clin Endoorinol. Metab 84:137-144. 
14. Raji A, Seely EW, Arky RA, Simonson DC 2001 Body fat 
distribution and insulin resistance in healthy Asian Indian and 
Caucasians  J.Clin Endocrinol Metab 86: 5366-5371. 
15. Ramachandran A, Snehalatha C, Latha E, Satyavani K, Vijay V 1998. 
Clustering of cardiovascular risk factors in urban Asian indians 
Diabetes care 21:967-971. 
` 
16. MC keigue PM, Faridi N, Siddle K, 1990 Relation of central obesity 
and insulin Resistance with high diabetes prevalence and 
cardiovascular risk in south Asian Lancet – 337-382-386. 
17. Dcrose GK, Zimmet PZ, Alberti KG, Brighan L, Carlin JB, 
Tuomilehto J, Knight LT, Gareeboo H 1993. Serum insulin 
distribution and reproducibility of the relationship between 2 hour 
insulin and plasma glucose levels in Asian Indian, Creole and Chinese 
Mauritians Mauritius NCD study group. Metabolism 42:1232-1241. 
18. Omar MA, Seedat MA, Dyer RB, Motala AA, knight LT, Becker PJ. 
1994.South African Indians shows a high prevalence of NIDDM and 
bimodality in Plasma glucose distribution patterns. Diabetes care 
17:70-73. 
19. Snehalatha C, Ramachandran A, satyavani K, vallabi MY, 
Viswanathan V1997 Computed axial tomographical scan 
measurement of abdominal fat distribution and its correlation with 
anthropometry and insulin secretion  in healthy Asian Indians. 
Metabolism 46:1220-1224. 
20. Feskens E.J.M., Tuomileh to, J., Stengaard J.H., Pekkanen J., 
Nissinen, A. and kromhout D (1995) Hypertension and overweight 
associated with hyperinsulinemia and  glucose tolerance: a 
` 
longituditinal study of the Finnish and Dutch cohorts of the seven 
countries study. Diabetologia 38,839-847. 
21. Brands M.W., Hildebrandt D.A., Mizelle H.L and Mall J.E (1991) 
Sustained hyperinsulinemia increase arterial pressure in conscious 
rats. Am. J.Physiol 260, R 764-768. 
22. Haffner S.M., Valde R.A., Hazuda HP., Mitchell B.D., Morales P.A 
and stern  M.P(1992) . Prospective analysis of insulin Resistance 
syndrome (syndrome X). Diabetes 41, 715-722. 
23. Despres J.P., Lamarche, B and Mauriege, Petal (1996) 
Hyperinsulinemia as an independent   risk factor for ischemic heart 
disease, NEJM 334, 952-957. 
24. Beatty O.L., Harper R., Sheriden B., Atkinsion A.B. and Bell 
P.M(1993) Insulin resistance in offspring of hypertensive parents 
BMJ 307, 92-96. 
25. Steinberg  H.O., Brechtel G. Insulin mediated muscle vasodilation is 
nitic oxide dependent. A novel action of insulin to increase nitric 
oxide release.  J clin invest 1994; 94:1172-79. 
26. De fron Zo R.A., Cooke  C.R. The effect of insulin on renal handling 
of Na. K, ca and phosphate in man . J.clin invest 1975;55 845-55 
` 
27. Barbato , A, Folker, EJ., et al Metabolic syndrome  and renal sodium 
handling in three ethnic groups living in England Diabetologia 
2004;47:40-46. 
28. Tooke  J.E., Hannemann, M.M. Adverse endothelial function and the 
insulin resistance syndrome J. intern Med 2000; 247:425-31 
29. Kuroda, S, Fuji T, et al. Role of Insulin Resistance in  the genesis of 
sodium sensitivity in essential hypertension, J.Hum Hypertens 1999, 
13:257-62. 
30. Baron , AD.1994 Hemodynamic actions of insulin Am.J. Physiol 
267;E187- E 202 
31. Anderson, E.A, Hoffman R.P ., Mark A.L Hyperlnsulinemia produces 
both sympathetic neural activation and vasodilatation in normal 
humans J.Clin Invest 1991; 87;2246-52 
32. Egan , B M., Insulin resistance and the sympathetic nervous system 
curr hypertens Rep 2002, 5: 247-54 
33. Mc. Keigue PM 1996. Metabolic consequences of obesity and body 
fat pattern: lessons from migrant studies Ciba Found Symp 201:54-
64: discussion 64-67, 188- 193. 
34. Mohan V, Deepa R,  Haranath S.P, Premalatha G, Rema M, Sastry 
N.G., Enas E.A. 1998 Lipoprotein (a) is an independent risk factor for 
` 
coronary artery disease in NIDDM patients in South India. Diabetes 
care 21:1819-1823. 
35. Lewis G.F., Uffelman K.D. Interaction between FFA and insulin in 
acute  control of VLDL production in  human J. Clin invest 1995;95: 
158-66. 
36. Lewis G.F, Steiner G.Acute effects of insulin in the control of VLDL 
production in humans. Diabetes care 1996; 19: 390-93. 
37. Eckel, R.M., Yost T.J., Alteration in lipoprotein lipase in insulin 
resistance . Int J.obes Relat Met disorder  1995; 19 (suppl) ; S 16-S21 
38. Murakami T, Longhi R, et al Triglycerides are major determinants of 
cholesterol esterification / transfer and HDL remodelling in human 
plasma Arterioscle Thromb vase Biol 1995; 15:1819-28. 
39. Brinton EA, Eisenberg  Increased apo A1 and A2 fractional catabolic 
rate in patients with low HDL levels with or without 
hypertriglyceidemia J Clin invest 1991; 87:536-44. 
40. Manzato E, Zambon Level and physiochemical properties of 
lipoprotein subclass in moderate hypertriglyceridemia Clin Acta 1993, 
219:57- 65. 
41. Kwiterovich Pojr. Clinical relevance of the  biochemical, metabolic 
and genetic factors that influence LDL heterogenecity Am.J. cardiol 
2002; 90; 30i-47i  
` 
42. Packard C.J. LDL subfractions and atherogenecity an hypothesis 
from the university of glascow Curr med. Opin 1996; 13:379-90 
43. Abdel – Maksoud M.F., H.O Kanson J.E. The complex role of 
triglycerides in cardiovascular disease Semin vase Med 2003; 2:       
325-34. 
44. Dudya V, Misra A, Pandey RM, Devina G., kumar G, vikram N.K. 
2001 BMI  does not accurately predict overweight  in Asian Indians in 
northern India Br, J. Nutr. 86:105-112. 
45. Misra A 2003 Body composition and the metabolic syndrome in 
Asian Indians: A saga of multiple adversities Natl med. J. India. 16:3-
7 
46. WHO. Western pacific region. The Asia pacific perspective 
Redefining obesity and its treatment WHO/IASD/IVIF, 2000. 
47. Lee S, Ross R. Inter individual variation in abdominal subcutaneous 
and visceral adipose tissue: influence of measurement site. J Appl 
physiology 2004; 97: 948-54.  
48. Aubest H, Alessi MC. Weak and non - independent association 
between plasma TAF I antigen levels and the insulin resistance 
syndrome  J.Thromb Haemost 2003; 1: 791 – 97.   
` 
49. Bajaj M, Banerji M.A. Type 2 Diabetes in south Asians; a 
pathophysiological focus on the Asian Indians epidemic. Curr Diab 
Rep 2 004; 4:231-218. 
50. Tanaka S, Horimai C.Ethnic differences in abdominal visceral fat 
accumulation between Japanese, African Americans and Caucasians : 
a meta analysis Acta Diabetol 2003; 40 (Suppl ) S 302- S 304. 
51. Guo Z, Jensen M.D, Johnson C.M. Regional post prandial FFA 
metabolism in different obesity phenotypes. Diabetes 1999; 48:          
1586-92. 
52. Randle P.J., Hales C.N. Garland P.B and Newson E.A (1963) The 
glucose fatty acid cycle,  its role in insulin sensitivity and metabolic 
disturbances of diabetes mellitus Lancet 1, 785-789. 
53. Griffin  M.E., Marcucci M.J., Cline G.W., Bell K. Barucci, N., Lee D  
Good year, L.J.,  Kraegen, E.W., white M.F., and shulman G.I (1999) 
.Free fatty acid induced insulin resitance is associated with  activation 
of protein kinase C theta and alterations in the insulin signalling 
cascade, Diabetes 48; 1270-74. 
54. Haffner S.M., Lehto  S., Ronnemaa T.,  Pyorala K.and Laasko M 
(1998) Morlality from coronary heart disease in subject with type 2 
diabetes and in non – diabetic subjects with and without prior 
myocardial infarction. NEJM 339: 229-234.   
` 
55. Bokemark L, Wikstrand  J., Attavalli S, Huthe J., Wedel H.and 
Fagerberg B (2001) Insulin resistance and intima - media thickness in 
carotid and femoral arteries of clinically healthy 58 years old men. 
The atherosclerosis  and insulin  resistance (AIR) study J. Intern Med 
249, 59-67. 
56. Howard G, O’ Leary D.H., Zaccaroo D, Rewers H, Hamman R, Selby 
J.V Saad M.F., Savage P and Bergman (1996) Insulin sensitivity and 
arthrosclerosis. Circulation 93, 1809-1817  
57. Sandholzer C, Hallman DM, Saha N, Sigurdsson G, Lackner C, 
Csanzar A, Boerwinkle E, Utermann G (1991) Effects of the 
apolipoprotein (a) Size, polymorphism on the lipoprotein (a) 
concentration in 7 ethnic groups. Hum Genet 86: 607-614. 
58. Markovitz J.H. Kulkarni K, Goldschmidt - dermont P,  kiefe C.I, 
Rustagi P, Sekar  P, Nanda N. 1998 Increased platelet activation and 
fibrinogen in Asian Indians. Potential implications  for coronary risk . 
Eur Heart J19 720-726. 
59. Nagi D.K, Knowler W.C, Hanson R.L., Ali V.M 1996 Plasminogen 
activator inhibitor (PAI-1) and non insulin dependent diabetes in Pima 
Indians, south Asians and Europeans Thromb Haemost 75: 921-927. 
` 
60. Chan .J.M., Rimm E.B., Colditz  G.A., stampfer  M. J., and Willett. 
W.C (1994). Obesity, fat distribution and weight gain as risk factors 
for clinical diabetes in men. Diabetes care 961-969. 
61. Marshall J.A., Bessesen D.H. and Hamman RF (1997) High saturated 
fat and low starch and fibre are associated with hyperinsulinemia in a 
non diabetic population, the san luis valley diabetes study, 
Diabetologia 40: 430-438. 
62. Vessb B, Unsitupa M, Hermansen K, Riccardi G, Rivellese A.A and 
Tapsell L.C et al., (2001) Substituting dietary saturated for 
monounsaturated  fat impairs insulin sensitivity in healthy men and 
women; the KANWU study Diabetologia 44:B12.319. 
63. Mc Keown N.M, Meigs JB, Lui S Wison P.W.F and Jacque P.F 
(2002) whole grain Intake is favourably associated with metabolic 
risk factors for type 2 diabetes and cardiovascular disease in the 
Framingham offspring study Am. J.Clin . Nutr 76: 390-398. 
64. Wood P.O, Stefanick M.L, Williams P.T and Haskell W.L (1991).The 
effect on plasma lipoproteins of a  prudent weight reducing diet, with 
or without exercise, in overweight men and women NEJM 325:             
461-466. 
` 
65. Kroteivski M, Handroukas L and Sjostrom L et al (1970) Effect of 
long term physical training on body fat, metabolism and blood 
pressure in obesity Metabolism 28: 650-658. 
66. Helmrick S.P, Ragland D.R., Leung R.W and Paffenbarger R.S 
(1991) Physical activity and reduced occurrence of non insulin 
dependent diabetes mellitus NEJM 325 147-152. 
67. Hemibrecht R, Wolf A and Giefen S. et al (2000) Effect of exercise 
on coronary endothelial function in patients with coronary artery 
disease, NEJM 342 454-460. 
68. Randeva H.S., Lewandowski K.C., Drzowoski J, Brooke-wavelle K, 
O’ Callaghan C, Hillhouse E.W and Prelevic G.H (2002) Exercise 
decreases plasma total homocysteine in overweight young women 
with polycystic ovary  syndrome . J .Clin Endocrin Metab 87:            
4496-4501. 
69. Stratton J.R., Chandler W.L and Schwart z R.S et al (1991) Effects of 
physical conditioning on fibrinolytic variables and fibrinogen in  
young and old healthy adults Circulation 83:16 
70. Rad Ziuk J. (2000) Insulin sensitivity and its Measurement: Structural 
commonalities among the methods J, Clin Endocrinol metab 85:4426-
4433. 
` 
71. Wallace T.M and Mathews D.R (2002) The assessment of insulin 
resistance in man. Diabet Med 19, 527-534.   
72. Bergman R.N, Finegood D.T and Andres R (1985) Assessment of 
insulin sensitivity in vivo Endocrine Rev 6:45 -86. 
73. De Fronzo  R.A., Tobin J.D and Ander M (1979) Glucose clamp 
technique ; a method for quantifying insulin secretion and resistance. 
Am J physiol 237 : E 214 – E 223.   
74. Kelley D.E and Mandarino L.J (2000) Fuel selection in human 
skeletal muscle in Inuslin resistance a re examination. Diabetes 49: 
677-683. 
75. Blaak E.E., Wagen Makers A.J., Glatz J.F Wolffenbuttfel B.H, 
Kemerink G.J., Langenberg C.J. Heidendal G.A and suris  W.H 
(2000) plasma FFA uitilisation and fatty acid binding protein content 
are diminished in type 2 diabetic muscle .Am J physiol Endocrinol 
metab 279 E 146-E154. 
76. Bergam R.N, Ider Y.Z, Bowden C.R and Cobelli (1979) Quantitative 
estimation of insulin sensitivity Am. J physiol 236; E667-E677. 
77. Weber K.M, Martin I.K, Best J.D, Alford F.P and Boston R.C (1989) 
Alternative method for minimal model analysis of intravenous 
giucose tolerance data Am J. Physiol 256, E524-535. 
` 
78. Matthews D.R, Hosker J.P, Rudenski A.S, Naylor B.A, Teacher D.F 
and Turner R.C (1985) Homeostasis model assessment: Insulin 
resistance and beta cell function from fasting plasma glucose and 
Insulin concentration in man. Dialetologia 28; 412-419.   
79. Katz A, Nambi S.S., Mather K, Baron A.D., Follman DA Sullivan G 
and Quoton M.J (2000)  Quantitative insulin sensitivity check index: a 
simple,  accurate method for assessing insulin sensitivity in humans . 
J.din endocrinol  Metab 85: 2402-2410. 
80. Expert committee on the diagnosis and classification of diabetes 
mellitus Report of the expert committee on the diagnosis and 
classification of diabetes mellitus. Diabetes care 1997; 20:1183- 97. 
81. Pyorala M,Miettinen H, Laaskso M.Pyorala K.Plama insulin and all 
cause, cardiovascular and non cardiovascular mortality; the 22 year 
follow up result of the Helsinki Policeman study. Diabetes care 2000; 
23:1097- 1020 
82. Despres J.P, Lamarche B, Mauriege P, Cantin B Hyperinsulinemia as 
an independent risk factor for ischemic heart disease. NEJM 1996. 
334: 952 – 957 
83. Rewers M, Zaccaro D, D’ Agostino R, Haffner S, Selby J.V Insulin 
resistance Atherosclerosis study investigator. Insulin sensitivity, 
` 
insulinemia and coronary artery disease: the Insulin Resistance 
Atherosclerosis study. Diabetes care 2004, 27:781-787  
84. Mansfield M.W., Heywood DM, Grant P.J. Circulating  levels of 
factor VII fibrinogen, Von willebrand factor and features of insulin 
resistance in first degree relatives of patients with NIDDM 
Circulation 1996; 94: 2171-2176. 
85. Inoue T,  Matsunaga R, Sakai Y, Yaguchi I, Takaya nagi                     
K, Marooka S. Insulin resistance affects endothelium dependent 
acetyl choline induced coronary artery response. Eur Heart J 2000; 
21:895-900. 
86. Yazici M, Demircan S, Aksakal E,Sahin H, Meric M, Dursun I et al. 
Plasma insulin, glucose and lipid count in patients with slow coronary 
flow, Turkish Andolu kardiyol Derg 2003;3:227-229. 
87. Ugur - Attun B, Altun A, Tatli E, Arikan E Relationship between 
Insulin Resistance assessed by HOMA- IR and exercise test varirables 
in asymptomatic middle aged patients with type diabetes J.Endocrinol 
invest 2004 ; 27:455-61.   
88. Takezako T, Saku K, Zhang B, Shiraik , Arakawa K. Insulin 
resistance and angiographical  characteristics  of coronary 
atherosclerosis Jpn Circ. J. 1999, 63:666-676  
` 
89. Radke P.W., VoswinkelM, Reith M, Kaiser A, Haager PK, Hanrath 
P, Hoffman R.Relation of fasting lnsulin plasma levels to restenosis 
after elective coronary stent implantation in patients without diabetes 
mellitus. Am J.Cardiol 2004; 93: 639-641. 
90. Corpus R.A, O’ Neill W.N, Dixon SR, Timmis G.C, Delvin W.H. 
Relation of HbA1C to rate of major adverse cardiac events in non 
diabetic patients undergoing percutaneous coronary revascularization 
Am J cardiol 2003:92:1282-1286. 
91. Sekiguchi M. Kurabayashi M, Adachi M, Oshima S Usefulness of 
insulin resistance measured by homeostais model assessment in 
predicting restenosis after coronary stent placement in non diabetic 
patients. Am. J cardiol 2004-93: 920-922.  
 
 
 
 
 
 
 
 
 
 
 
` 
 
 
 
 
 
 
 
 
 
ABBREVIATION 
 
 
 
 
 
 
 
 
` 
ABBREVIATION 
 CAD   -  CORONARY ARTERY DISEASE 
BMI   –  BODY MASS INDEX 
WHR  –  WAIST HIP RATIO  
SBP   –  SYSTOLIC BLOOD PRESSURE 
DBP   –  DIASTOLIC BLOOD PRESSURE  
HDL   –  HIGH DENSITY LIPOPROTEIN  
LDL   –  LOW DENSITY LIPOPROTEIN  
TGL   – TRIGLYCERIDES 
TC   –  TOTAL CHOLESTEROL  
FBS   –  FASTING BLOOD SUGAR 
SI   –  SERUM INSULIN  
HOMA–IR  – HOMEOSTATIC MODEL ASSESSMENT –  
INSULIN  RESISTANCE  
IRS   –  INSULIN RECEPTOR SUBSTRATE  
IR   –  INSULIN RESISTANCE 
VLDL -  VERY LOW DENSITY LIPOPROTEIN  
APO B  – APOLIPOPROTEIN B 
MRI   –  MAGNETIC RESONANCE IMAGING 
NEFA -  NON ESTERIFIED FATTY ACIDS 
DM   – DIABETES MELLITUS  
` 
MI   –  MYOCARDIAL INFARCTION  
TNF- ALPHA –TUMOUR NECROSIS FACTOR ALPHA 
LPL  -  LIPOPROTEIN LIPASE 
PAI- 1 - PLASMINOGEN ACTIVATOR INHIBITOR -1 
HSL  -  HORMONE SENSITIVE LIPASE 
GLUT -4 -  GLUCOSE TRANSPORTER -4 
PCOS  –  POLYCYSTIC OVARIAN SYNDROME 
OGTT  – ORAL GLUCOSE TOLERANCE TEST 
QUICKI  – QUANTITATIVE INSULIN SENSITIVITY  
CHECK INDEX 
G/IRATIO  – GLUCOSE /INSULIN RATIO 
STEMI  –  ST ELEVATION MYOCARDIAL INFARCTION  
NSTEMI  –  NON ST ELEVATION MYOCARDIAL  
INFARCTION 
ACS   – ACUTE CORONARY SYNDROME  
RVMI  –  RIGHT VENTRICULAR MYOCARDIAL  
INFARCITON  
ECG   –  ELECTROCARDIOGRAM  
IRAS   –  INSULIN RESISTANCE ATHEROSCLEROSIS  
STUDY 
TIMI  -  THROMBOLYSIS IN MYOCARDIAL  
INFARCTION  
MACE  –  MAJOR ADVERSE CARDIAC EVENTS. 
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PROFOMA 
 
 
` 
PROFOMA 
History  
Name   Age   Sex  
Occupation   op.no 
Address  
Diabetes : Y/N Hypertension: Y/N  
H/o Stable angina: 
Smoker : 
alcoholic: 
Family H/O DM/HT/CAD: 
 
 
Examination : 
Height : Weight:  
BMI : WHR: 
Pulse  : BP : 
CVS  : RS: 
Abd : CNS: 
 
` 
Investigations  
Blood sugar Fasting :   PP :  
Blood Urea :                              Serum creatinine  
Urine Alb :      Sugar :   deposits :  
Lipid Profile : 
TC :  TGL :   HDL:   LDL : 
ECG :    Echocardiogram:   
Fasting insulin:    HOMA –IR : 
` 
 
 
 
MASTER CHART 
 
 
 
 
 
 
 
 
 
` 
SL.NO NAME AGE  SEX GENDER FAM HIS SMOKING ALCOHOL BMI WHR SBP DBP HDL LDL TGL TC FBS SI  HOMA IR  GROUP 
1 Vincent  51 M        1 1 0 1 28.4 0.91 100 70 37 122 209 244 105 25.4 6.58 1 
2 Susainat 58 M        1 1 1 0 24.62 0.88 100 70 29 110 207 220 103 28.4 7.22 1 
3 Thangara 64 M        0 1 1 1 29.4 0.92 110 70 31 88 163 147 102 32.4 8.16 1 
4 Balarama 65 M        0 1 0 0 23.8 0.82 130 80 34 95 131 158 105 22.9 5.93 1 
5 Elumalai 44 M        0 0 0 1 24.6 0.86 140 80 37 95 157 190 106 19.6 5.12 1 
6 Mathivan 50 M        0 1 1 0 25.11 0.92 160 90 39 116 199 226 105 23.6 6.11 1 
7 Radhakri 47 M        1 0 0 1 27.6 0.84 130 80 33 120 205 246 108 25 6.66 1 
8 Akila    44 F        0 0 0 1 28.3 0.93 120 80 27 126 215 266 104 29.5 7.57 1 
9 Nasreen  56 F        0 1 0 0 29.6 0.96 130 80 29 104 159 196 109 39.5 10.6 1 
10 Akila    42 F        0 1 0 0 21.64 0.76 120 80 27 96 145 186 99 19.8 4.84 1 
11 baskar   41 M        1 1 1 0 20.07 0.74 120 80 29 76 123 108 98 17.2 4.16 1 
12 Govindan 45 M        1 1 1 1 22.8 0.72 140 70 32 90 152 155 106 22.4 5.86 1 
13 Pencilli 65 M        0 0 1 1 26.37 0.9 130 80 35 132 209 264 108 32.9 8.77 1 
14 Govindar 56 M        0 0 1 1 29.68 0.92 140 90 31 96 163 189 102 21 5.29 1 
15 Padmavathy 55 F        0 0 0 0 21.6 0.76 130 80 37 102 165 176 91 29.5 6.62 1 
16 Lakshmi  49 F        0 1 0 0 19.8 0.63 120 80 27 92 153 156 95 18 4.22 1 
17 Chinnath 55 M        1 0 1 1 18.6 0.71 130 80 25 90 147 168 94 17.8 4.13 1 
18 Selvam   48 M        1 0 0 0 22.5 0.82 120 80 27 92 167 184 98 19.5 4.71 1 
19 Vijayala 63 F        0 1 0 0 23.43 0.76 130 70 29 96 165 182 96 14.2 3.36 1 
20 Rajendra 52 M        1 1 0 1 28.62 0.92 130 80 33 124 213 258 108 15.8 4.21 1 
21 Saravana 48 M        1 1 1 1 21.8 0.68 140 70 35 122 207 268 103 14.6 3.71 1 
22 Chinnasa 45 M        1 0 1 1 27.8 0.94 130 80 39 126 209 276 105 14.5 3.75 1 
23 Munusamy 46 M        1 0 1 1 22.5 0.68 120 70 35 88 157 161 93 13.8 3.16 1 
24 Kuppan   55 M        1 1 0 1 27.5 0.92 150 90 37 86 163 194 102 14 3.52 1 
25 Balaji   47 M        1 1 1 0 19.6 0.82 120 70 39 82 153 182 97 14 3.35 1 
26 Murali   48 M        1 0 0 0 26.4 0.76 130 80 33 98 167 226 104 17.8 4.57 1 
27 Mahohar  44 M        1 1 1 0 24.2 0.74 120 80 31 86 157 186 102 19.8 4.98 1 
28 Mani     42 M        1 1 1 0 21.6 0.68 130 80 29 8 147 174 96 14.6 3.46 1 
29 Rugavan  40 M        1 0 1 0 22.8 0.86 140 90 27 126 205 252 108 24.8 6.61 1 
30 Ganatham 58 M        1 0 0 1 23.6 0.78 130 80 35 122 213 264 109 29.6 7.96 1 
31 Jilal    54 M        1 0 0 0 28.6 0.94 140 80 37 120 227 284 107 28.8 7.6 1 
32 Daniel   52 M        1 1 1 0 22.5 0.76 120 80 33 96 143 169 94 18.6 4.31 1 
33 Arunacha 48 M        1 0 0 0 23.8 0.82 130 80 31 102 163 192 96 17.8 4.21 1 
` 
34 Shanthi  50 F        0 0 0 1 26.2 0.8 140 80 33 104 189 220 98 29.6 7.16 1 
35 Kathires 52 M        1 0 1 1 27.6 0.92 140 80 35 120 209 226 104 26.4 6.77 1 
36 Yusuf    56 M        1 1 1 0 28.2 0.94 130 80 37 122 213 244 108 32.4 8.64 1 
37 Malini   52 F        0 0 0 0 22.4 0.78 120 80 31 96 147 186 102 16.8 4.23 1 
38 Madhavan 44 M        1 0 1 0 23.6 0.76 130 80 29 92 145 182 92 14.6 3.31 1 
39 Vinodhin 50 F        0 1 0 0 21.6 0.68 120 80 31 86 141 176 96 13.8 3.27 1 
40 Srinivas 55 M        1 0 0 0 26.4 0.88 140 80 35 104 183 192 98 21.6 5.22 1 
41 Usha     52 F        0 0 0 0 20.6 0.66 110 70 33 86 165 168 88 14.4 3.12 1 
42 Chandra  56 F        0 1 0 0 21.2 0.62 100 70 29 82 163 272 92 16.8 3.81 1 
43 Durai    57 M        1 0 1 0 22.4 0.72 110 70 31 90 165 178 102 21.4 5.38 1 
44 Sakuntha 68 F        0 0 0 0 28.4 0.94 110 80 37 122 209 246 104 26.8 6.88 1 
45 Venkates 46 M        1 1 1 0 27.6 0.96 140 80 35 128 217 264 108 24.6 6 1 
46 Jayaraj  44 M        1 0 1 0 24.6 0.82 130 80 33 102 205 202 104 24.8 6.36 1 
47 Thanagam 52 F        0 0 0 0 22.4 0.78 120 80 29 98 149 186 98 21.4 5.17 1 
48 Subraman 53 M        1 0 0 0 23.6 0.8 110 80 31 92 163 182 102 19.6 4.93 1 
49 Gajendra 50 M        1 0 0 0 24.8 0.96 120 80 27 94 169 178 88 22.6 4.91 1 
50 Dhanalax 66 F        0 0 0 0 20.6 0.68 100 80 29 86 153 168 86 15.5 3.29 1 
51 Devaraj  55 M        1 0 0 0 22.6 0.84 130 90 46 92 132 184 109 13.3 3.3 0 
52 Ravi     49 M        1 0 1 1 23.4 0.66 100 70 44 126 186 251 102 10.6 2.6 0 
53 Kumar    54 M        1 0 1 1 20.8 0.77 130 100 47 70 133 144 103 11.1 2.8 0 
54 Yobu     55 M        1 0 1 1 21.2 0.68 140 90 42 84 134 167 96 10.6 2.51 0 
55 Rajendra 45 M        1 0 0 0 20.64 0.82 130 90 46 102 136 186 82 10.2 2.06 0 
56 Pushpa   55 F        0 0 0 0 21.2 0.71 130 80 48 103 142 196 76 11.5 2.15 0 
57 Manjula  56 F        0 1 0 0 22.6 0.58 120 80 42 104 138 168 85 14 2.93 0 
58 Latha    54 F        0 0 0 0 21.8 0.66 130 80 38 96 134 188 78 10.8 2.02 0 
59 Lalitha  57 F        0 0 0 0 27.6 0.86 120 80 42 115 194 230 95 12 2.8 0 
60 Manner   45 M        1 0 1 0 19.2 0.63 130 80 44 84 106 164 102 11.6 2.92 0 
61 Viswanat 42 M        1 0 1 1 243.2 0.76 120 80 46 122 146 247 84 11.2 2.32 0 
62 Subraman 51 M        1 1 0 0 22.08 0.69 120 70 42 104 136 108 89 10.6 2.33 0 
63 Geetha   58 F        0 1 0 0 21.35 0.7 110 70 44 94 108 116 83 10.6 2.61 0 
64 Padma    42 F        0 1 0 0 31.62 0.88 120 70 42 126 184 266 99 12.9 2.81 0 
65 Muhamed  47 M        1 1 0 0 22.8 0.68 190 80 44 98 125 189 85 11.5 1.99 0 
66 Prabu    43 M        1 0 0 0 23.6 0.74 100 70 42 94 128 169 78 9.6 1.96 0 
67 Ettiappa 47 M        1 0 0 0 22.4 0.82 100 80 44 92 134 168 104 10.2 3.21 0 
` 
68 Mahima   48 F        0 1 0 0 24.6 0.8 100 70 42 88 142 196 101 12.5 3.21 0 
69 Veerarag 56 M        1 0 0 0 24.22 0.72 110 70 39 122 189 246 90 10.2 2.26 0 
70 Jayaraj  56 M        1 0 1 1 22.8 0.68 120 70 42 106 196 184 96 11.8 2.79 0 
71 Santhosh 55 M        1 0 0 0 20.8 0.72 110 70 40 98 188 208 92 8.2 1.86 0 
72 Jahir Hu 40 M        1 0 1 1 22.6 0.67 100 70 36 88 142 196 86 11.5 2.44 0 
73 Vijaya   48 F        0 0 0 0 28.6 0.84 108 70 44 122 186 232 91 9.6 2.16 0 
74 Chellamm 51 F        0 0 0 0 24.6 0.72 130 80 44 98 136 208 86 10.8 2.25 0 
75 Bee Bee  55 F        0 0 0 0 22.6 0.82 140 70 42 84 106 184 82 11.4 2.3 0 
76 Parvathy 50 F        0 0 0 0 24.6 0.78 130 80 44 110 164 220 86 10.6 2.25 0 
77 Saraswat 62 F        0 0 1 0 20.8 0.8 140 90 46 92 136 196 102 14 3.52 0 
78 Vasantha 58 F        0 0 0 0 28.6 0.94 150 90 42 82 132 189 80 10.9 2.15 0 
79 Lakshmi  55 F        0 1 0 0 31.1 0.92 130 80 36 78 128 157 88 7.5 1.62 0 
80 Thenmozh 54 F        0 0 0 0 22.6 0.68 120 80 42 92 132 185 84 8.3 1.72 0 
81 Vijayala 64 F        0 0 0 0 23.43 0.72 130 80 40 90 128 180 96 14.2 3.36 0 
82 Selvam   58 M        1 1 1 0 21.8 0.66 120 80 38 88 126 190 109 12.3 3.31 0 
83 Frakash  54 M        1 0 0 0 22.6 0.64 120 80 42 96 134 176 98 11.2 2.71 0 
84 Vinodh   66 M        1 0 1 1 23.4 0.74 130 80 44 102 142 188 86 12.6 2.67 0 
85 Kala     54 F        0 0 0 0 24.8 0.82 120 80 42 108 156 216 96 13.8 3.27 0 
86 Vikram   42 M        1 0 0 0 21.6 0.72 130 80 44 104 166 204 104 14.6 3.75 0 
87 Sekar    44 M        1 0 1 1 22.8 0.8 140 80 36 94 136 189 88 12.6 2.73 0 
88 Sankar   46 M        1 1 0 0 23.6 0.66 130 80 38 96 134 194 92 3.2 2.99 0 
89 Gunasaga 44 M        1 0 0 1 24.8 0.92 140 80 40 108 186 226 106 15.8 4.13 0 
90 Rajendra 56 M        1 0 1 0 26.5 0.74 130 80 42 96 126 128 92 12.8 2.9 0 
91 Kumar    52 M        1 1 0 0 18.5 0.68 120 80 38 94 124 189 88 11.6 2.52 0 
92 Ganesh   44 M        1 0 0 1 20.5 0.66 130 80 40 92 134 192 86 10.8 2.29 0 
93 Vignesh  52 M        1 0 0 1 21.5 0.71 120 80 37 90 132 184 102 12.5 3.14 0 
94 Seetha   46 F        0 1 0 0 22.5 0.72 120 80 38 96 142 168 94 13.5 3.13 0 
95 Raju     48 M        1 0 1 1 24.5 0.78 130 80 44 98 186 184 92 14.5 3.29 0 
96 Sundaram 49 M        1 0 0 0 22.6 0.64 140 80 42 94 142 194 102 12.2 3.07 0 
97 Chandran 51 M        1 1 0 0 20.5 0.71 120 80 36 86 126 178 90 11.8 2.62 0 
98 Saravana 46 M        1 0 1 1 18.5 0.66 130 80 40 92 138 194 82 2.3 2.49 0 
99 Senthil  52 M        1 0 0 0 20.75 0.68 120 80 42 88 128 174 84 14.2 2.94 0 
100 Murugesa 48 M        1 0 0 0 22.75 0.72 130 80 38 98 138 184 88 14.6 3.71 0 
